3.9 Article

FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?

Journal

CURRENT DIABETES REVIEWS
Volume 12, Issue 3, Pages 223-230

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1573399811666150804104858

Keywords

FoxO1; metabolic disorders; diabetes; diabetic complications; obesity; FoxO1 inhibitors; AS1842856

Funding

  1. DST -INSPIRE [IF131160]
  2. The Science & Engineering Research Board - Department of Science & Technology (SERB- DST), Govt. of India [SR/FT/LS-154/2011, SB/ EMEQ-053/2013]
  3. University Grant Commission Major Research Project (UGC-MRP) [42-702/2013]

Ask authors/readers for more resources

FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ` omni-functional' owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases' pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available